Literature DB >> 24140713

Hemin therapy improves kidney function in male streptozotocin-induced diabetic rats: role of the heme oxygenase/atrial natriuretic peptide/adiponectin axis.

Joseph Fomusi Ndisang1, Ashok Jadhav.   

Abstract

Diabetic nephropathy is characterized by elevated macrophage infiltration and inflammation. Although heme-oxygenase (HO) is cytoprotective, its role in macrophage infiltration and nephropathy in type 1 diabetes is not completely elucidated. Administering the HO inducer, hemin, to streptozotocin-diabetic rats suppressed renal proinflammatory macrophage-M1 phenotype alongside several proinflammatory agents, chemokines, and cytokines including macrophage inflammatory protein 1α (MIP-1α), macrophage-chemoattractant protein-1 (MCP-1), TNF-α, IL-1β, IL-6, nuclear factor-κB (NF-κB), and aldosterone, a stimulator of the inflammatory/oxidative transcription factor, NF-κB. Similarly, hemin therapy attenuated extracellular matrix/profibrotic proteins implicated in renal injury including fibronectin, collagen-IV, and TGF-β1 and reduced several renal histopathological lesions such as glomerulosclerosis, tubular necrosis, tubular vacuolization, and interstitial macrophage infiltration. Furthermore, hemin reduced markers of kidney dysfunction like proteinuria and albuminuria but increased creatinine clearance, suggesting improved kidney function. Correspondingly, hemin significantly enhanced the antiinflammatory macrophage-M2 phenotype, IL-10, adiponectin, HO-1, HO activity, and atrial natriuretic-peptide (ANP), a substance that abates TNF-α, IL-6, and IL-1β, with parallel increase of urinary cGMP, a surrogate marker of ANP. Contrarily, coadministering the HO inhibitor, chromium-mesoporphyrin with the HO-inducer, hemin nullified the antidiabetic and renoprotective effects, whereas administering chromium-mesoporphyrin alone abrogated basal HO activity, reduced basal adiponectin and ANP levels, aggravated hyperglycemia, and further increased MCP-1, MIP-1α, aldosterone, NF-κB, TNF-α, IL-6, IL-1β, proteinuria/albuminuria, and aggravated creatinine clearance, thus exacerbating renal dysfunction, suggesting the importance of the basal HO-adiponectin-ANP axis in renoprotection and kidney function. Collectively, these data suggest that hemin ameliorates diabetic nephropathy by selectively enhancing the antiinflammatory macrophage-M2 phenotype and IL-10 while concomitantly abating the proinflammatory macrophage-M1 phenotype and suppressing extracellular matrix/profibrotic factors with reduction of renal lesions including interstitial macrophage infiltration. Because aldosterone stimulate NF-κB, which activates cytokines like TNF-α, IL-6, IL-1β that in turn stimulate chemokines such as MCP-1 and MIP-1α to promote macrophage-M1 infiltration, the hemin-dependent potentiation of the HO-adiponectin-ANP axis may account for reduced macrophage infiltration and inflammatory insults in streptozotocin-diabetic rats.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24140713     DOI: 10.1210/en.2013-1050

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  21 in total

Review 1.  Heme Oxygenase-1 in Kidney Health and Disease.

Authors:  Jeremie M Lever; Ravindra Boddu; James F George; Anupam Agarwal
Journal:  Antioxid Redox Signal       Date:  2016-05-26       Impact factor: 8.401

2.  Macrophage polarization in kidney diseases.

Authors:  Shaojiang Tian; Shi-You Chen
Journal:  Macrophage (Houst)       Date:  2015

Review 3.  Therapeutic approaches to diabetic nephropathy--beyond the RAS.

Authors:  Beatriz Fernandez-Fernandez; Alberto Ortiz; Carmen Gomez-Guerrero; Jesus Egido
Journal:  Nat Rev Nephrol       Date:  2014-05-06       Impact factor: 28.314

Review 4.  The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis.

Authors:  Jessica Hurtubise; Krystie McLellan; Kevin Durr; Oluwadara Onasanya; Daniel Nwabuko; Joseph Fomusi Ndisang
Journal:  Curr Atheroscler Rep       Date:  2016-12       Impact factor: 5.113

Review 5.  Application of carbon monoxide for treatment of acute kidney injury.

Authors:  Atsunori Nakao; Taihei Yamada; Keisuke Kohama; Norichika Yoshie; Noritomo Fujisaki; Joji Kotani
Journal:  Acute Med Surg       Date:  2014-04-23

Review 6.  Present and future in the treatment of diabetic kidney disease.

Authors:  Borja Quiroga; David Arroyo; Gabriel de Arriba
Journal:  J Diabetes Res       Date:  2015-04-07       Impact factor: 4.011

7.  The risk of heart failure and cardiometabolic complications in obesity may be masked by an apparent healthy status of normal blood glucose.

Authors:  Shuchita Tiwari; Manish Mishra; Ashok Jadhav; Courtney Gerger; Paul Lee; Lynn Weber; Joseph Fomusi Ndisang
Journal:  Oxid Med Cell Longev       Date:  2013-12-14       Impact factor: 6.543

Review 8.  Regulation of Monocytes/Macrophages by the Renin-Angiotensin System in Diabetic Nephropathy: State of the Art and Results of a Pilot Study.

Authors:  Claudine Moratal; Audrey Laurain; Mourad Naïmi; Thibault Florin; Vincent Esnault; Jaap G Neels; Nicolas Chevalier; Giulia Chinetti; Guillaume Favre
Journal:  Int J Mol Sci       Date:  2021-06-02       Impact factor: 5.923

9.  The heme oxygenase system suppresses perirenal visceral adiposity, abates renal inflammation and ameliorates diabetic nephropathy in Zucker diabetic fatty rats.

Authors:  Joseph Fomusi Ndisang; Ashok Jadhav; Manish Mishra
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

10.  Oxidative stress and inflammation in obesity, diabetes, hypertension, and related cardiometabolic complications.

Authors:  Joseph Fomusi Ndisang; Alfredo Vannacci; Sharad Rastogi
Journal:  Oxid Med Cell Longev       Date:  2014-02-27       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.